ACM
CLVS

ACT Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

ACT Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,000
Closed -$70K – 140
2021
Q2 		$70K Buy
+12,000
New +$70.3K 0.04% 103

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACT Capital Management's CLVS Position: Q3 2021 in Review

ACT Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 12,000 shares — an estimated $70K sold.

ACT Capital Management first reported a position in CLVS in Q2 2021 and held it in 1 quarter. The position peaked at $70K in Q2 2021. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

  • ACT Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 12,000 Clovis Oncology, Inc. shares in Q3 2021, an estimated $70K.
  • ACT Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Clovis Oncology, Inc. position peaked at $70K in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.